Kiniksa Pharmaceuticals Ltd. priced its IPO of 8,477,777 class A common shares at $18 each.
The company expects to raise gross proceeds of about $152.6 million through the offering, which is expected to close May 29, subject to customary closing conditions.
Underwriters have a 30-day option to buy up to an additional 1,271,666 class A common shares at the offering price.
The shares are expected to start trading May 24 on the Nasdaq Global Select Market under the symbol KNSA.
Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are acting as joint book-running managers for the offering, with JMP Securities LLC and Wedbush Securities Inc. as co-managers.
Bermuda-based Kiniksa Pharmaceuticals develops treatments for debilitating diseases with significant unmet medical need.
